Our group of prognostic and predictive blood biomarkers – GlyHealth, reliably measure and track chronic inflammation processes in the body. Unlike current inflammation markers, this is done without interference from acute inflammation and can give early warning signs even at very early subclinical stages of inflammatory diseases. Blood tests based on these biomarkers can also be used to track fitness of immune system and effectiveness of anti-inflammatory intervention.
We help: Diagnosed patients with inflammatory conditions such as Inflammatory Bowel Disease or at high risk of developing such conditions to detect their condition at early stage, monitor it and personalise treatments.
Benefits:
We help:
Medical or other healthcare practitioners responsible for caring for patients with Chronic Inflammatory Diseases to improve patients outcome and personalise treatments. Benefits:
We help: Drug companies developing anti-inflammatory therapeutics to improve cost effectiveness and efficiency of trials.
Benefits:
